Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06887413
Recruiting Not applicable

TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.

NCT06887413 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2026-02-18
Last updated
2026-04-21

Condition(s) studied

Anterior Myocardial Infarction

Investigational drug(s) / intervention(s)

THROMBOASPIRATION WITH INDIGO SYSTEM

THROMBOASPIRATION WITH INDIGO SYSTEM: Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.

Study summary

The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
INCLUSION CRITERIA 1. Age \>18 and \<75 years old 2. Acute anterior STEMI with ≥2 mm in two (2) or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads V1-V4 AND anterior wall motion abnormality noted on a diagnostic quality left ventriculogram or echocardiogram 3. Culprit lesion proximal or mid LAD at coronary angiography 4. TIMI thrombus grading \> 3 or TIMI flow 0 after guidewire crossing the lesion. 5. Patient presents to the hospital between 1 - 6 hours of ischemic pain onset 6. Patient indicated for primary percutaneous coronary intervention (PPCI) EXCLUSION CRITERIA 1. Unable to give Informed consent. 2. Life expectancy \< 1 year. 3. Contraindication to PCI 4. STEMI due to stent thrombosis 5. Spontaneous coronary aretery dissection 6. Patient undergone any kind of maneuvers to restore flow before randomization 7. Unwitnessed cardiac arrest OR ≥30 minutes of cardiopulmonary resuscitation (CPR) prior to enrolment OR any cardiac arrest with impairment in mental status, cognition or any global or focal neurological deficit 8. New onset of stroke symptoms and NIHSS \>2, prior to index procedure 9. Known intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media. 10. Active severe bleeding 11. Severe hepatic/kidney impairment 12. Administration of fibrinolytic therapy within 24 hours prior to enrolment 13. Cardiogenic shock defined as systemic hypotension (systolic BP \<90 mmHg or the need for inotropes/pressors to maintain a systolic BP \>90 mmHg), plus one (1) of the following: any requirement for pressors / inotropes prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion, or use of IABP or any other mechanical circulatory support device 14. Inferior STEMI or suspected right ventricular failure 15. Severe valvulopathy 16. Acute cardiac mechanical complication: LV-free wall rupture OR interventricular septum rupture OR acute mitral regurgitation Medical Conditions \& History: 1. Suspected or known pregnancy 2. Suspected systemic active infection 3. History or known hepatic insufficiency prior to catheterization 4. Undergoing a renal replacement therapy 5. Chronic obstructive pulmonary disease (COPD) with home oxygen therapy or on chronic steroid therapy 6. Contraindication to perform MRI or use gadolinium \[creatinine clearance (CrCl) \<30 mL/min, non-compatible implant, claustrophobia\] Cardiovascular history 1. Known or evidence of prior MI, including pathologic Q-waves in non-anterior leads 2. Prior coronary artery bypass graft surgery (CABG) or LAD PCI 3. History of heart failure (documented history of EF \<40% or documented hospitalization for HF within 1 year prior to screening 4. Prior aortic valve surgery or TAVR 5. Left bundle branch block (new or old) 6. History of stroke/TIA within 3 months prior to screening

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IRCCS Ospedale San Raffaele Milan Milani Recruiting

More Ceric Sàrl trials in Italy

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06887413 on ClinicalTrials.gov ↗ ← All trials in Italy